ESGCT/BSGCT Annual Congress

164 days

10 hours

40 mins

Our Partners

We are very grateful for support from our partners, please click on any logos below to head to their website.

If you would like to see your logo here, head over to our Sponsorship Guide page to find out how we can work together!

Platinum

Adverum

Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. ADVM-022, utilizes a propriety vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. ADVM-022 is administered as a one-time intravitreal injection, designed to deliver long-term efficacy and reduce the burden of frequent anti-VEGF injections, optimize patient compliance and improve vision outcomes for wet AMD and diabetic retinopathy patients. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control.

Biopharma Excellence

Biopharma Excellence is THE consulting company for biopharmaceutical drug development and regulatory strategies. Biopharma Excellence supports clients to bring their ideas to approval. The Biopharma Excellence team comprises experienced experts with proven track records coming from agencies, industry or service providers. We are THE experts for advanced therapy medicinal products (ATMP) such as cell, tissue and gene therapies. Biopharma Excellence has supported numerous unique ATMP development projects by preparing and executing tailored strategies in order to speed up the process from early-stage development to initiation of clinical studies up to marketing authorization.

Oxgene

OXGENE find solutions to seemingly impossible problems. We develop new technologies in mammalian cell engineering along the whole spectrum from discovery science to engineering at scale. Our unique combination of precision engineering and breakthrough science with advanced robotics and bioinformatics accelerates the rational design, manufacture and processing of complex biologics.
We work at the very edge of impossible to solve the problem of high titre virus manufacture for gene therapy treatments. We do this with high titre, high quality, suspension transient viral manufacturing systems, and with AAV and lentiviral packaging and producer cell lines. We address the challenge of speed and consistency in gene editing with our high throughput automated CRISPR platform, and we deliver the breakthrough needed to discover antibodies to membrane proteins through novel mammalian display techniques.

Sarepta

Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) and more recently in gene therapies for 6 Limb-girdle muscular dystrophy diseases (LGMD), Charcot-Marie-Tooth (CMT), MPS IIIA, Pompe and other CNS-related disorders, totaling over 20 therapies in various stages of development. The Company’s programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. Sarepta is fueled by an audacious but important mission: to profoundly improve and extend the lives of patients with rare genetic-based diseases.

Gold

Cevec Pharmaceuticals

CEVEC is a center of expertise for the production of biopharmaceuticals using a unique human cell-based expression system.
CAP®GT is a fully scalable manufacturing platform for viral vector production. CEVEC has successfully developed CAP®GT suspension cell-derived viral packaging cell lines, including a stable, helper virus-free AAV production platform, which enable better scale-up and competitive production costs when compared to adherent cell culture systems. CAP®GT suspension cell lines grow to high cell densities and show excellent productivity for a broad range of viruses. Gene therapy vectors such as lentiviral, adenoviral, and adeno-associated viral (AAV) vectors can be produced at industrial scale.
CAP®Go enables the production of proteins “beyond antibodies”. The CAP®Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for the highly efficient production of a broad range of difficult to express recombinant proteins with authentic human post-translational modifications or on demand tailor-made glycosylation patterns.

Charles River Laboratories

The journey to market for a cellular or novel gene therapy is challenging given the unique and high specialized nature of each individual program, so it is crucial to choose a partner with proven experience developing these types of treatments and navigating the regulatory hurdles often associated with them. With over 70 years of experience, Charles River has a unique and comprehensive portfolio to support the development and execution of cellular and gene therapy programs from animal model selection to discovery and safety evaluations through to clinical and CMC testing support with expertise in a wide range of therapeutic areas. Our facilities in the United States, Canada, Britain, Finland, Netherlands, and Germany form a global scientific and regulatory network, allowing us to provide our clients with flexible, comprehensive solutions to optimize results and achieve milestones in order to make it to market on time. 
 

Human Gene Therapy

Established in 1990, Human Gene Therapy is the leading peer-reviewed journal publishing exceptional, multidisciplinary research embracing all aspects of gene therapy - from basic research to new technologies to clinical development. In 2020 the Journal will mark three impressive decades by unveiling a dramatic new redesign and a renewed editorial mission. Stop by booth 29 to pick up free copies of Human Gene Therapyexplore a suite of CRISPR and gene therapy publications, and learn more about the exciting new changes coming next year. Human Gene Therapy serves as the Official Journal of ESGCT.

Repligen

Inspiring advances in bioprocessing, Repligen is a technology leader in bioprocess filtration, pre-packed chromatography and Protein A ligands development. Propelled by a culture of innovation and collaboration, and with a focus on cost and process efficiencies, our people and our technologies help meet critical bioproduction demands worldwide. Named one of the fastest growing biotech companies in the USA, Repligen is headquartered in Boston, MA with major manufacturing sites in Massachusetts, California, Sweden and Germany.
 

Yposkesi

Yposkesi is one of the largest Contract Development & Manufacturing Organizations (CDMO) in Europe for AAV and lentiviral vector production. A spin-off from the world-class gene therapy pioneer Genethon, Yposkesi capitalizes on more than 20 years’ expertise in biotherapeutic research to offer customers full integrated services; bioprocess development (USP & DSP), from small/pilot to large production scale, analytical development, GMP manufacturing of clinical batches of lentiviral and AAV vectors and regulatory support. Its current 50,000 sq ft (approx. 5,000m2) state-of-the-art facility designed for high efficiency houses four independent manufacturing suites for bulk drug substance and two Fill&Finish suites. Yposkesi is extending this capacity. By 2021 it will double its global footprint to 100,000 ft2  (approx. 10,000m2) with a second large-scale facility designed for commercial production and EMA and FDA compliance. Yposkesi invests significantly in innovation and bioprocessing to deliver on high quality projects, cost-effectively.

Silver

Bio-Rad Laboratories

Bio-Rad Laboratories is a world leader in providing a broad range of products for the life science research and diagnostic markets. In our Life Science Group, we build the industry leading instruments, apparatus and consumables that enable advances in all key research areas from Cell Biology and Genomics through to Proteomics and Food Safety.
 
Our innovative solutions include the pioneering Droplet Digital™ PCR alongside an extensive range of systems and reagents for qPCR, chromatography, cell analysis, immunoassay, electrophoresis, western blotting, imaging and more. For complete details of our comprehensive range of products contact your local office or visit www.discover.bio-rad.com.  
 

Biocair

Biocair is a global specialist courier with over 30 years of dedicated experience in the pharmaceutical, biotechnology and life science sectors. Specifically, we provide dedicated, specialised logistics services – both the systems and the people – for the scientific sector and our services are the most comprehensive of its kind available on the market.

The company has built up a unique, client-centric approach by employing scientists in front- line logistics positions and assembling a team of best-in-class industry experts in quality, cold chain and regulatory compliance amongst others. Biocair focuses on providing the most comprehensive time-sensitive and temperature-controlled logistics services available whilst delivering flexible, tailored, cost effective solutions to all clients.

The Biocair network spans more than 850 locations in over 160 countries across Europe, Africa, Asia and the Americas.

Cellex

MANY TASKS. ONE NAME: CELLEX CELL PROFESSIONALS – WE CARE FOR LIFE
Cellex is offering a broad spectrum of services for clinical as well as for research institutions in the field of cellular therapies.
Cellex started its operation with a Cellex collection center in 2001 offering stem cell collections from unrelated donors for leukaemia patients. Today Cellex is the largest and most experienced center worldwide.
Today in our state-of-the-art GMP facilities different cell therapy products are manufactured using various techniques (separation, genetic modification, expansion); processes are adapted to customers’ needs.
Our donor pool “CellCommunity” allows us to support R&D as well as clinical trials and supply research institutions worldwide with cell material.
Centralized management of all different runs with the help of secure and efficient IT solutions, developed by Cellex as well as transports worldwide support are an essential part.
Beside Cellex develops individual cell therapies and is conducting early clinical studies on new therapeutic approaches.
 

FinVector

FinVector is a world leader in the research/development and cGMP manufacture of Viral-Based Gene Therapy products, with state-of-the-art facilities and a highly experienced scientific team working in the gene therapy market. We deliver a tailored service to meet and exceed our clients’ needs. With our scientific expertise and industry knowledge FVT help clients take viral-based products from pre-clinical through to commercial phase.

Gyros Protein Technologies (GPT)

Gyros Protein Technologies provides enabling peptide synthesis and bioanalytical solutions that help scientists increase biomolecule performance and productivity in research, drug discovery, pre-clinical and clinical development, and bioprocess applications.  Our low to mid-scale peptide synthesizer platforms are the new PurePepTM Chorus, Tribute®, Prelude® X, Symphony® X, and Sonata® XT. These solutions and our chemistries deliver uncompromising purity, flexibility, and quality for discovery and pre-clinical studies of simple to complex multifunctional peptides. Proprietary high performance nanoliter-scale immunoassay platforms, Gyrolab® xPand, Gyrolab® xP workstation and Gyrolab xPlore™, are used by scientists in leading pharmaceutical, biotech, CRO, and CMO companies for bioanalytical applications such as pharmacokinetics/pharmacodynamics, immunogenicity, and quantitating bioprocess-related impurities. Our peptide synthesis and bioanalytical solutions accelerate your discovery, development, and manufacturing of safer biotherapeutics. Gyros Protein Technologies is a division of Mesa Laboratories - www.mesalabs.com.

KCT

KCT is newly formed research center in Kuopio, Finland. We provide high quality basic and translational research. Professional team and laboratories with cutting edge devices are providing scientific know-how and modern technologies to develop advanced therapies. We undertake science in collaboration with academic groups all over the world. Link to FinVector's GMP manufacturing, quality and regulatory teams ensures product path from research to patients.
 

Kuhner shaker

Kuhner shaker, founded in 1949 in Basel, Switzerland, is a science-first shaker manufacturer renowned worldwide for our uncompromising shakers, incubator shakers, and orbitally shaken bioreactors complying with GMP regulations. From bench top shakers to large scale industrial shaking machines, we offer machines of the highest quality.

Kuhner provides a personal and committed service. We offer comprehensive consultations for our products and accessories to guarantee that you have the optimal equipment for your processes and experiments right away. Based on our longtime experience and our partnerships with research facilities we provide application-oriented support and training for our products. Special requests from customers are actioned without fuss.

Lonza Pharma & Biotech

At Lonza Pharma & Biotech, we provide contract development and manufacturing services that enable pharma and biotech companies to bring medicines to patients in need.  From the building blocks of life to the final drug product, our solutions are created to simplify your outsourcing experience and provide a reliable outcome when you expect it. Our extensive track record includes commercialization of pioneering therapies and manufacturing of a wide variety of biological and chemical drugs. We continuously invest to solve not just the current, but also the future challenges. Together, let’s bring your next medicine to life.
 

NHSBT

NHS Blood and Transplant is a national organisation within the NHS dedicated to saving and improving lives.
Our Cellular and Molecular Therapies function offers broad experience and expertise in the provision and manufacture of cell and gene therapies through our national network of GMP grade and MHRA licensed facilities.
NHSBT partner with academic, commercial and NHS organisations supporting novel cell and gene therapy programmes from concept through to clinical trial, operating a ‘not for profit’ model. 
We welcome expressions of interest for partnerships with organisations striving to develop the future of medicine in the advanced therapies space.

Polyplus-transfection

Polyplus-transfection applies its 15+ year expertise to the development of novel transfection solutions up to GMP grade for high yield transient protein and antibody production in CHO and HEK-293 cells, as well as for viral vector production for Gene and Cell Therapy (PEIpro product range).

QPS

QPS’ mission is to accelerate pharmaceutical breakthroughs across the globe by delivering custom-built research services in discovery, toxicology, DMPK, gene therapy and preclinical and clinical research. QPS is known for proven quality standards, technical expertise, client satisfaction, and turnkey laboratories and sites. With QPS, you gain a client-dedicated team with experienced project managers as single contact-points for maximum efficiency. We have worked on 50+ GT programs covering DMPK, biodistribution and shedding studies, and bioanalysis (PK, ADA, Nab) in all phases and multiple modalities. QPS offers the full range of clinical research services including project management, monitoring, data management, biostatistics, and safety. We also have a number of CLIA assays ready to use for in/exclusion criteria. Ready for your next gene/cell therapy program and prepared for rare disease studies, QPS can fast-track your project by performing complex studies with remarkable agility. 

Sartorius

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2018, the company earned sales revenue of €1,212.2 million, and currently employs some 5,800 people.
 
 

Stilla Technologies

Stilla Technologies focuses on accelerating the development of next-generation genetic tests by providing innovative instrumentation for digital PCR. In 2016, Stilla Technologies launched the Naica System, the first and only dPCR solution to offer 3-color multiplexing. Other key features of the system are the speed, simplicity and versatility of its workflow.